Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

BOSÁKOVÁ Michaela VAŘECHA Miroslav HAMPL Marek DURAN Ivan NITĂ Alexandru BUCHTOVÁ Marcela DOSEDELOVA Hana MACHÁT Radek XIE Yangli NI Zhenhong MARTIN Jorge H. CHEN Lin JANSEN Gert KRAKOW Deborah KREJČÍ Pavel

Year of publication 2018
Type Article in Periodical
Magazine / Source Human molecular genetics
MU Faculty or unit

Faculty of Medicine

Citation
Web https://academic.oup.com/hmg/article/27/6/1093/4816205
Doi http://dx.doi.org/10.1093/hmg/ddy031
Keywords ciliary function; fibroblast growth factor; FGFR3
Description Cilia project from almost every cell integrating extracellular cues with signaling pathways. Constitutive activation of FGFR3 signaling produces the skeletal disorders achondroplasia (ACH) and thanatophoric dysplasia (TD), but many of the molecular mechanisms underlying these phenotypes remain unresolved. Here, we report in vivo evidence for significantly shortened primary cilia in ACH and TD cartilage growth plates. Using in vivo and in vitro methodologies, our data demonstrate that transient versus sustained activation of FGF signaling correlated with different cilia consequences. Transient FGF pathway activation elongated cilia, while sustained activity shortened cilia. FGF signaling extended primary cilia via ERK MAP kinase and mTORC2 signaling, but not through mTORC1. Employing a GFP-tagged IFT20 construct to measure intraflagellar (IFT) speed in cilia, we showed that FGF signaling affected IFT velocities, as well as modulating cilia-based Hedgehog signaling. Our data integrate primary cilia into canonical FGF signal transduction and uncover a FGF-cilia pathway that needs consideration when elucidating the mechanisms of physiological and pathological FGFR function, or in the development of FGFR therapeutics.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.